Wiesje M Van Der Flier

List of Publications by Citations

810 papers	30,905 citations	93 h-index	151 g-index
970 ext. papers	38,913 ext. citations	5.9 avg, IF	7.03 L-index

#	Paper	IF	Citations
810	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. *Alzheimers and Dementia*, **2014**, 10, 844-52	1.2	1219
809	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1924-38	27.4	842
808	Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nature Genetics*, **2019**, 51, 404-413	36.3	771
807	CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. *JAMA - Journal of the American Medical Association*, **2009**, 302, 385-93	27.4	758
806	Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 126-35	5.5	430
805	Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1939-49	27.4	379
804	The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. *Ageing Research Reviews*, **2016**, 25, 13-23	12	330
803	Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. *Stroke*, **2008**, 39, 1414-20	6.7	299
802	Early-versus late-onset Alzheimer's disease: more than age alone. *Journal of Alzheimers Disease*, **2010**, 19, 1401-8	4.3	282
801	Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. *Neurobiology of Aging*, **2013**, 34, 2023-36	5.6	279
800	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. *Brain*, **2015**, 138, 2732-49	11.2	275
799	Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. *Stroke*, **2005**, 36, 2116-20	6.7	266
798	Consensus classification of posterior cortical atrophy. *Alzheimers and Dementia*, **2017**, 13, 870-884	1.2	261
797	The characterisation of subjective cognitive decline. *Lancet Neurology, The*, **2020**, 19, 271-278	24.1	259
796	Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. *BMC Neuroscience*, **2009**, 10, 101	3.2	258
795	Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. *Clinical Chemistry*, **2010**, 56, 248-53	5.5	256
794	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. *Journal of Alzheimers Disease*, **2015**, 48 Suppl 1, S63-86	4.3	253

793	Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. *Neurobiology of Aging*, **2012**, 33, 2018-28	5.6	253
792	Epidemiology and risk factors of dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2005**, 76 Suppl 5, v2-7	5.5	250
791	Implementation of subjective cognitive decline criteria in research studies. *Alzheimer's and Dementia*, **2017**, 13, 296-311	1.2	245
790	Alzheimer's disease. *Lancet, The*, **2021**, 397, 1577-1590	40	245
789	Optimizing patient care and research: the Amsterdam Dementia Cohort. *Journal of Alzheimer's Disease*, **2014**, 41, 313-27	4.3	243
788	Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. *Neurology*, **2009**, 72, 999-1007	6.5	238
787	Prevalence and severity of microbleeds in a memory clinic setting. *Neurology*, **2006**, 66, 1356-60	6.5	238
786	Brain microbleeds and Alzheimer's disease: innocent observation or key player?. *Brain*, **2011**, 134, 335-44	11.2	235
785	Visual assessment of posterior atrophy development of a MRI rating scale. *European Radiology*, **2011**, 21, 2618-25	8	223
784	Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. *Neurology*, **2012**, 78, 47-54	6.5	220
783	Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE e4 allele. *Lancet Neurology, The*, **2011**, 10, 280-8	24.1	218
782	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. *Brain*, **2015**, 138, 1327-38	11.2	211
781	Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. *Neuroradiology*, **2007**, 49, 967-76	3.2	209
780	Blood-brain barrier P-glycoprotein function in Alzheimer's disease. *Brain*, **2012**, 135, 181-9	11.2	205
779	The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?. *Alzheimer's and Dementia*, **2014**, 10, 713-723.e2	1.2	204
778	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. *Alzheimer's and Dementia*, **2015**, 11, 1180-90	1.2	201
777	Vascular cognitive impairment. *Nature Reviews Disease Primers*, **2018**, 4, 18003	51.1	195
776	Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. *Brain*, **2008**, 131, 3286-98	11.2	195

775	Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: the CADDementia challenge. *NeuroImage*, **2015**, 111, 562-79	7.9	193
774	Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. *Stroke*, **2009**, 40, 3455-60	6.7	179
773	Suspected non-Alzheimer disease pathophysiology--concept and controversy. *Nature Reviews Neurology*, **2016**, 12, 117-24	15	174
772	Cerebral blood flow measured with 3D pseudocontinuous arterial spin-labeling MR imaging in Alzheimer disease and mild cognitive impairment: a marker for disease severity. *Radiology*, **2013**, 267, 221-30	20.5	170
771	Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer's disease. *NeuroImage* , **2012**, 59, 3085-93	7.9	160
770	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. *JAMA Neurology*, **2015**, 72, 1275-80	17.2	152
769	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. *Human Molecular Genetics*, **2014**, 23, 6139-46	5.6	152
768	Incident lacunes influence cognitive decline: the LADIS study. *Neurology*, **2011**, 76, 1872-8	6.5	148
767	Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. *Journal of Nuclear Medicine*, **2009**, 50, 1464-70	8.9	145
766	Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. *Human Brain Mapping*, **2015**, 36, 4421-37	5.9	142
765	A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. *Annals of Clinical Biochemistry*, **2009**, 46, 235-40	2.2	140
764	Cerebrospinal fluid A42 is the best predictor of clinical progression in patients with subjective complaints. *Alzheimers and Dementia*, **2013**, 9, 481-7	1.2	139
763	Longitudinal cognitive decline in subcortical ischemic vascular disease--the LADIS Study. *Cerebrovascular Diseases*, **2009**, 27, 384-91	3.2	139
762	Profile of cognitive impairment in chronic heart failure. *Journal of the American Geriatrics Society*, **2007**, 55, 1764-70	5.6	139
761	CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. *Neurobiology of Aging*, **2007**, 28, 1070-4	5.6	139
760	Impact of molecular imaging on the diagnostic process in a memory clinic. *Alzheimers and Dementia* , **2013**, 9, 414-21	1.2	137
759	Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. *Annals of Neurology*, **2018**, 84, 648-658	9.4	137
758	Memory complaints in patients with normal cognition are associated with smaller hippocampal volumes. *Journal of Neurology*, **2004**, 251, 671-5	5.5	134

757	Age and diagnostic performance of Alzheimer disease CSF biomarkers. *Neurology*, **2012**, 78, 468-76	6.5	133
756	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. *Alzheimer's and Dementia*, **2019**, 15, 888-898	1.2	131
755	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. *Neurology*, **2013**, 80, 1048-56	6.5	131
754	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. *Alzheimer's and Dementia*, **2016**, 12, 154-163	1.2	129
753	Consensus guidelines for lumbar puncture in patients with neurological diseases. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 8, 111-126	5.2	128
752	Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. *Alzheimer's and Dementia*, **2019**, 15, 465-476	1.2	127
751	Microglial activation in Alzheimer's disease: an (R)-[□□C]PK11195 positron emission tomography study. *Neurobiology of Aging*, **2013**, 34, 128-36	5.6	126
750	White matter hyperintensities rather than lacunar infarcts are associated with depressive symptoms in older people: the LADIS study. *American Journal of Geriatric Psychiatry*, **2006**, 14, 834-41	6.5	123
749	Amsterdam Dementia Cohort: Performing Research to Optimize Care. *Journal of Alzheimer's Disease*, **2018**, 62, 1091-1111	4.3	122
748	Early onset Alzheimer's disease is associated with a distinct neuropsychological profile. *Journal of Alzheimer's Disease*, **2012**, 30, 101-8	4.3	121
747	Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease. *Neurobiology of Aging*, **2013**, 34, 2014-22	5.6	120
746	Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2006**, 77, 439-42	5.5	119
745	Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. *European Journal of Nuclear Medicine and Molecular Imaging*, **2012**, 39, 990-1000	8.8	116
744	Magnetization transfer imaging in normal aging, mild cognitive impairment, and Alzheimer's disease. *Annals of Neurology*, **2002**, 52, 62-7	9.4	116
743	Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. *JAMA Neurology*, **2014**, 71, 855-62	17.2	113
742	Progression of mild cognitive impairment to dementia: contribution of cerebrovascular disease compared with medial temporal lobe atrophy. *Stroke*, **2009**, 40, 1269-74	6.7	112
741	Microglial activation in healthy aging. *Neurobiology of Aging*, **2012**, 33, 1067-72	5.6	110
740	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. *Neurology*, **2012**, 79, 1809-16	6.5	110

739	Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. *Journal of Nuclear Medicine*, **2009**, 50, 191-7	8.9	108
738	Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. *Clinical Chemistry and Laboratory Medicine*, **2011**, 49, 353-66	5.9	108
737	Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. *Radiology*, **2008**, 248, 590-8	20.5	107
736	Brain magnetic resonance imaging abnormalities in patients with heart failure. *European Journal of Heart Failure*, **2007**, 9, 1003-9	12.3	107
735	Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. *Current Medical Research and Opinion*, **2008**, 24, 2561-74	2.5	106
734	Preclinical AD predicts decline in memory and executive functions in subjective complaints. *Neurology*, **2013**, 81, 1409-16	6.5	104
733	Longitudinal changes of CSF biomarkers in memory clinic patients. *Neurology*, **2007**, 69, 1006-11	6.5	104
732	Clinical relevance of improved microbleed detection by susceptibility-weighted magnetic resonance imaging. *Stroke*, **2011**, 42, 1894-900	6.7	103
731	A meta-analysis of genome-wide association studies identifies multiple longevity genes. *Nature Communications*, **2019**, 10, 3669	17.4	102
730	Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study. *Journal of Neurology*, **2006**, 253, 1189-96	5.5	101
729	CSF biomarkers predict rate of cognitive decline in Alzheimer disease. *Neurology*, **2009**, 73, 1353-8	6.5	100
728	Hippocampal atrophy in Alzheimer disease: age matters. *Neurology*, **2006**, 66, 236-8	6.5	100
727	MRI biomarkers of vascular damage and atrophy predicting mortality in a memory clinic population. *Stroke*, **2009**, 40, 492-8	6.7	99
726	Brain atrophy accelerates cognitive decline in cerebral small vessel disease: the LADIS study. *Neurology*, **2012**, 78, 1785-92	6.5	98
725	Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. *Neurology*, **2013**, 80, 1124-32	6.5	97
724	Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. *Neurology*, **2010**, 74, 1954-60	6.5	97
723	Diagnostic imaging of patients in a memory clinic: comparison of MR imaging and 64-detector row CT. *Radiology*, **2009**, 253, 174-83	20.5	97
722	CSF biomarker levels in early and late onset Alzheimer's disease. *Neurobiology of Aging*, **2009**, 30, 1895-906	5.6	97

721	Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. *Neurology*, **2015**, 84, 508-15	6.5	96
720	Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage. *Frontiers in Aging Neuroscience*, **2013**, 5, 58	5.3	95
719	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. *JAMA Psychiatry*, **2018**, 75, 84-95	14.5	94
718	Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. *Journal of Alzheimer's Disease*, **2014**, 41, 801-7	4.3	93
717	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. *Brain*, **2012**, 135, 2115-25	11.2	91
716	The contribution of medial temporal lobe atrophy and vascular pathology to cognitive impairment in vascular dementia. *Stroke*, **2007**, 38, 3182-5	6.7	88
715	Standardized Assessment of Automatic Segmentation of White Matter Hyperintensities and Results of the WMH Segmentation Challenge. *IEEE Transactions on Medical Imaging*, **2019**, 38, 2556-2568	11.7	87
714	CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. *Neurobiology of Aging*, **2008**, 29, 669-75	5.6	87
713	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. *Brain*, **2015**, 138, 2701-15	11.2	86
712	Declining functional connectivity and changing hub locations in Alzheimer's disease: an EEG study. *BMC Neurology*, **2015**, 15, 145	3.1	85
711	Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2009**, 80, 478-83	5.5	85
710	Brain network alterations in Alzheimer's disease measured by eigenvector centrality in fMRI are related to cognition and CSF biomarkers. *Human Brain Mapping*, **2014**, 35, 2383-93	5.9	84
709	Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 547-51	5.5	82
708	Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset. *Psychological Medicine*, **2009**, 39, 1907-11	6.9	81
707	Differential diagnosis of neurodegenerative diseases using structural MRI data. *NeuroImage: Clinical*, **2016**, 11, 435-449	5.3	81
706	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. *Alzheimer's Research and Therapy*, **2015**, 7, 59	9	80
705	Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. *Neurology*, **2013**, 80, 359-65	6.5	80
704	Single-subject grey matter graphs in Alzheimer's disease. *PLoS ONE*, **2013**, 8, e58921	3.7	80

703	CSF -synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. *Journal of Alzheimer's Disease*, **2010**, 22, 87-95	4.3	80
702	Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. *Diabetic Medicine*, **2007**, 24, 166-71	3.5	80
701	Diagnostic impact of [F]flutemetamol PET in early-onset dementia. *Alzheimer's Research and Therapy*, **2017**, 9, 2	9	79
700	Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. *Neurobiology of Aging*, **2010**, 31, 758-64	5.6	77
699	Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. *Alzheimer's and Dementia*, **2018**, 14, 707-722	1.2	76
698	Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. *Neurology*, **2008**, 70, 1836-41	6.5	76
697	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-1-42 Analysis Results. *Clinical Chemistry*, **2018**, 64, 576-585	5.5	76
696	Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. *Neurology*, **2001**, 57, 2117-20	6.5	75
695	CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. *Neurology*, **2009**, 72, 1056-61	6.5	74
694	Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. *European Radiology*, **2009**, 19, 2826-33	8	74
693	Global dynamical analysis of the EEG in Alzheimer's disease: frequency-specific changes of functional interactions. *Clinical Neurophysiology*, **2008**, 119, 837-41	4.3	74
692	Prevalence of amyloid-pathology in distinct variants of primary progressive aphasia. *Annals of Neurology*, **2018**, 84, 729-740	9.4	74
691	Disruption of functional brain networks in Alzheimer's disease: what can we learn from graph spectral analysis of resting-state magnetoencephalography?. *Brain Connectivity*, **2012**, 2, 45-55	2.7	73
690	White matter lesion progression in LADIS: frequency, clinical effects, and sample size calculations. *Stroke*, **2012**, 43, 2643-7	6.7	73
689	Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study. *Brain*, **2017**, 140, 1466-1485	11.2	72
688	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. *Neurobiology of Aging*, **2012**, 33, 2272-81	5.6	72
687	Neuroimaging and correlates of cognitive function among patients with heart failure. *Dementia and Geriatric Cognitive Disorders*, **2007**, 24, 418-23	2.6	71
686	Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2005**, 76, 1497-500	5.5	71

685	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. *JAMA Neurology*, **2018**, 75, 1062-1070	17.2	70
684	Diffusion-weighted imaging and cognition in the leukoariosis and disability in the elderly study. *Stroke*, **2010**, 41, e402-8	6.7	70
683	Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. *Neurology*, **2007**, 69, 1491-7	6.5	70
682	Cerebral perfusion in the predementia stages of Alzheimer's disease. *European Radiology*, **2016**, 26, 506-14	4	69
681	The effect of APOE genotype on clinical phenotype in Alzheimer disease. *Neurology*, **2006**, 67, 526-7	6.5	69
680	Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. *Neurology*, **2018**, 90, e149-e156	6.5	68
679	Alzheimer's disease first symptoms are age dependent: Evidence from the NACC dataset. *Alzheimer's and Dementia*, **2015**, 11, 1349-57	1.2	67
678	Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. *Journal of Neurology, Neurosurgery and Psychiatry*, **2017**, 88, 113-118	5.5	66
677	The blood brain barrier in Alzheimer's disease. *Vascular Pharmacology*, **2017**, 89, 12-18	5.9	66
676	BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. *Journal of Alzheimer's Disease*, **2010**, 20, 253-60	4.3	66
675	Early-onset dementia is associated with higher mortality. *Dementia and Geriatric Cognitive Disorders* , **2008**, 26, 147-52	2.6	66
674	Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?. *European Radiology*, **2015**, 25, 3050-9	8	65
673	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. *European Radiology*, **2017**, 27, 1169-1175	8	65
672	On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. *Stroke*, **2008**, 39, 3083-5	6.7	65
671	Interaction of medial temporal lobe atrophy and white matter hyperintensities in AD. *Neurology*, **2004**, 62, 1862-4	6.5	65
670	Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. *Alzheimer's and Dementia*, **2017**, 13, 531-540	1.2	64
669	Reliability and sensitivity of visual scales versus volumetry for evaluating white matter hyperintensity progression. *Cerebrovascular Diseases*, **2008**, 25, 247-53	3.2	64
668	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. *Alzheimer's and Dementia*, **2016**, 12, 862-71	1.2	64

667	Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 425-32	5.5	63
666	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. *Alzheimer's Research and Therapy*, **2018**, 10, 5	9	63
665	Relationship between progression of brain white matter changes and late-life depression: 3-year results from the LADIS study. *British Journal of Psychiatry*, **2012**, 201, 40-5	5.4	63
664	Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. *European Journal of Human Genetics*, **2017**, 25, 973-981	5.3	62
663	Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. *Neurology*, **2018**, 90, e1231-e1239	6.5	62
662	Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2015**, 1, 505-12	5.2	62
661	Increased number of microinfarcts in Alzheimer disease at 7-T MR imaging. *Radiology*, **2014**, 270, 205-11	20.5	62
660	Microbleeds do not affect rate of cognitive decline in Alzheimer disease. *Neurology*, **2012**, 79, 763-9	6.5	62
659	Cerebral blood flow by using pulsed arterial spin-labeling in elderly subjects with white matter hyperintensities. *American Journal of Neuroradiology*, **2008**, 29, 1296-301	4.4	62
658	Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. *Molecular Psychiatry*, **2017**, 22, 153-160	15.1	61
657	Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations. *Neuropsychology Review*, **2017**, 27, 245-257	7.7	61
656	Trajectories of cognitive decline in different types of dementia. *Psychological Medicine*, **2015**, 45, 1051-9	6.9	60
655	Prevalence of cortical superficial siderosis in a memory clinic population. *Neurology*, **2014**, 82, 698-704	6.5	60
654	Neurological signs in relation to type of cerebrovascular disease in vascular dementia. *Stroke*, **2008**, 39, 317-22	6.7	60
653	Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. *Neurobiology of Aging*, **2013**, 34, 2488-94	5.6	59
652	Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. *Neurology*, **2009**, 73, 935-40	6.5	59
651	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. *Journal of Neurology, Neurosurgery and Psychiatry*, **2016**, 87, 235-43	5.5	58
650	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. *JAMA Neurology*, **2017**, 74, 1481-1491	17.2	58

649	The use of EEG in the diagnosis of dementia with Lewy bodies. *Journal of Neurology, Neurosurgery and Psychiatry*, **2008**, 79, 377-80	5.5	57
648	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. *Alzheimer's Research and Therapy*, **2018**, 10, 76	9	56
647	Magnetic resonance imaging predictors of cognition in mild cognitive impairment. *Archives of Neurology*, **2007**, 64, 1023-8		55
646	EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. *Neurobiology of Aging*, **2017**, 57, 133-142	5.6	54
645	Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. *Journal of Alzheimer's Disease*, **2012**, 29, 319-27	4.3	54
644	Combination of plasma amyloid beta and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. *Alzheimer's Research and Therapy*, **2020**, 12, 118	9	54
643	Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. *Radiology*, **2016**, 279, 838-48	20.5	52
642	White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. *Stroke* , **2015**, 46, 2661-4	6.7	51
641	Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: a 3-year follow-up of the LADIS study cohort. *Journal of the Neurological Sciences*, **2011**, 307, 100-5	3.2	51
640	Cognitive impairment in Alzheimer's disease is modified by APOE genotype. *Dementia and Geriatric Cognitive Disorders*, **2007**, 24, 98-103	2.6	51
639	Cognitive decline in AD and mild cognitive impairment is associated with global brain damage. *Neurology*, **2002**, 59, 874-9	6.5	51
638	Alzheimer's disease: The state of the art in resting-state magnetoencephalography. *Clinical Neurophysiology*, **2017**, 128, 1426-1437	4.3	50
637	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. *Acta Neuropathologica*, **2019**, 138, 237-250	14.3	50
636	Prognostic Factors for Cognitive Decline After Intracerebral Hemorrhage. *Stroke*, **2015**, 46, 2773-8	6.7	50
635	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. *Journal of Alzheimer's Disease*, **2016**, 54, 287-95	4.3	50
634	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. *Neurobiology of Aging*, **2016**, 38, 214.e7-214.e10	5.6	49
633	Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimer's Disease. An MEG Study with Virtual Electrodes. *Frontiers in Human Neuroscience*, **2016**, 10, 238	3.3	49
632	□Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. *Movement Disorders*, **2018**, 33, 1724-1733	7	49

631	Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. *Brain*, **2018**, 141, 3443-3456	11.2	49
630	Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic. *Alzheimer's and Dementia*, **2015**, 11, 523-32	1.2	48
629	PLD3 variants in population studies. *Nature*, **2015**, 520, E2-3	50.4	47
628	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. *Journal of Alzheimer's Disease*, **2015**, 48, 711-20	4.3	47
627	Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. *Journal of Neurology, Neurosurgery and Psychiatry*, **2010**, 81, 882-4	5.5	47
626	Small vessel versus large vessel vascular dementia: risk factors and MRI findings. *Journal of Neurology*, **2008**, 255, 1644-51; discussion 1813-4	5.5	47
625	Distinct perfusion patterns in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies. *European Radiology*, **2014**, 24, 2326-33	8	46
624	Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2015**, 46, 1103-10	4.3	46
623	Single-subject gray matter graph properties and their relationship with cognitive impairment in early- and late-onset Alzheimer's disease. *Brain Connectivity*, **2014**, 4, 337-46	2.7	46
622	Microbleeds relate to altered amyloid-β metabolism in Alzheimer's disease. *Neurobiology of Aging*, **2012**, 33, 1011.e1-9	5.6	46
621	Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. *Alzheimer's and Dementia*, **2017**, 13, 1226-1236	1.2	45
620	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. *Lancet Neurology, The*, **2019**, 18, 1034-1044	24.1	45
619	Resting state functional connectivity differences between behavioral variant frontotemporal dementia and Alzheimer's disease. *Frontiers in Human Neuroscience*, **2015**, 9, 474	3.3	45
618	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. *Brain*, **2016**, 139, 2528-39	11.2	45
617	Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2017**, 72, 846-854	6.4	44
616	MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. *Frontiers in Aging Neuroscience*, **2017**, 9, 117	5.3	44
615	Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. *Neurobiology of Aging*, **2012**, 33, 1591-8	5.6	44
614	Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. *Radiology*, **2016**, 281, 865-875	20.5	44

613	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 6, 143-151	5.2	43
612	The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. *Alzheimer's Research and Therapy*, **2017**, 9, 27	9	43
611	The Dutch Parelsnoer Institute--Neurodegenerative diseases; methods, design and baseline results. *BMC Neurology*, **2014**, 14, 254	3.1	42
610	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. *Neurology*, **2014**, 82, 1768-75	6.5	42
609	Associations between patterns of EEG abnormalities and diagnosis in a large memory clinic cohort. *Dementia and Geriatric Cognitive Disorders*, **2009**, 27, 18-23	2.6	42
608	Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. *Dementia and Geriatric Cognitive Disorders*, **2007**, 23, 42-6	2.6	42
607	Gray matter network disruptions and amyloid beta in cognitively normal adults. *Neurobiology of Aging*, **2016**, 37, 154-160	5.6	41
606	Prevalence and clinical significance of epileptiform EEG discharges in a large memory clinic cohort. *Dementia and Geriatric Cognitive Disorders*, **2010**, 29, 432-7	2.6	41
605	Late-onset dementia: structural brain damage and total cerebral blood flow. *Radiology*, **2005**, 236, 990-5	20.5	41
604	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 2340-7	5.6	40
603	EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer's disease and controls. *Neurobiology of Aging*, **2016**, 41, 122-129	5.6	40
602	Subjective Memory Complaints in APOEe4 Carriers are Associated with High Amyloid-Burden. *Journal of Alzheimer's Disease*, **2016**, 49, 1115-22	4.3	40
601	Widespread disruption of functional brain organization in early-onset Alzheimer's disease. *PLoS ONE*, **2014**, 9, e102995	3.7	40
600	Microbleeds in vascular dementia: clinical aspects. *Experimental Gerontology*, **2012**, 47, 853-7	4.5	40
599	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. *Lancet Neurology, The*, **2021**,	24.1	40
598	A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. *Human Brain Mapping*, **2017**, 38, 4703-4715	5.9	39
597	Microbleeds, Mortality, and Stroke in Alzheimer Disease: The MISTRAL Study. *JAMA Neurology*, **2015**, 72, 539-45	17.2	39
596	Blood-based metabolic signatures in Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 8, 196-207	5.2	39

595	CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. *Journal of Alzheimer's Disease*, **2009**, 16, 601-7	4.3	39
594	Transcranial Doppler blood flow assessment in patients with mild heart failure: correlates with neuroimaging and cognitive performance. *Congestive Heart Failure*, **2008**, 14, 61-5		39
593	The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. *Alzheimer's Research and Therapy*, **2014**, 6, 27	9	38
592	Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects. *Journal of Alzheimer's Disease*, **2010**, 20, 445-52	4.3	38
591	Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. *Neurology*, **2009**, 73, 2079-85	6.5	38
590	The heart-brain connection: a multidisciplinary approach targeting a missing link in the pathophysiology of vascular cognitive impairment. *Journal of Alzheimer's Disease*, **2014**, 42 Suppl 4, S443-51	4.3	37
589	Loss of EEG Network Efficiency Is Related to Cognitive Impairment in Dementia With Lewy Bodies. *Movement Disorders*, **2015**, 30, 1785-93	7	37
588	Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. *Journal of Alzheimer's Disease*, **2017**, 56, 687-697	4.3	36
587	Prevalence of the apolipoprotein E ε4 allele in amyloid β-positive subjects across the spectrum of Alzheimer's disease. *Alzheimer's and Dementia*, **2018**, 14, 913-924	1.2	36
586	Serum leptin is not altered nor related to cognitive decline in Alzheimer's disease. *Journal of Alzheimer's Disease*, **2015**, 44, 809-13	4.3	36
585	More atrophy of deep gray matter structures in frontotemporal dementia compared to Alzheimer's disease. *Journal of Alzheimer's Disease*, **2015**, 44, 635-47	4.3	36
584	Investigation of resting-state EEG functional connectivity in frontotemporal lobar degeneration. *Clinical Neurophysiology*, **2008**, 119, 1732-1738	4.3	36
583	New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population. *Dementia and Geriatric Cognitive Disorders*, **2010**, 30, 1-7	2.6	35
582	Patients' and caregivers' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2017**, 3, 314-322	6	34
581	Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study. *Journal of Neurology*, **2013**, 260, 1014-21	5.5	34
580	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. *Scientific Reports*, **2017**, 7, 13333	4.9	33
579	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. *Neurobiology of Aging*, **2016**, 46, 235.e1-9	5.6	33
578	The added value of 18-fluorodeoxyglucose-positron emission tomography in the diagnosis of the behavioral variant of frontotemporal dementia. *American Journal of Alzheimer's Disease and Other Dementias*, **2014**, 29, 607-13	2.5	33

577	Comparison of the Alzheimer's Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in differentiating elderly individuals with different degrees of white matter changes. The LADIS Study. *Dementia and Geriatric Cognitive Disorders*, **2007**, 24, 73-81	2.6	33
576	Early onset APOE E4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains. *European Neuropsychopharmacology*, **2015**, 25, 1010-7	1.2	32
575	The Missing Link in the Pathophysiology of Vascular Cognitive Impairment: Design of the Heart-Brain Study. *Cerebrovascular Diseases Extra*, **2017**, 7, 140-152	2.1	32
574	Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease. *Human Brain Mapping*, **2016**, 37, 978-88	5.9	32
573	Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease. *Neurobiology of Aging*, **2016**, 38, 21-31	5.6	32
572	Applying the ATN scheme in a memory clinic population: The ABIDE project. *Neurology*, **2019**, 93, e1635-e1646	5.5	32
571	EEG abnormalities in early and late onset Alzheimer's disease: understanding heterogeneity. *Journal of Neurology, Neurosurgery and Psychiatry*, **2011**, 82, 67-71	5.5	32
570	Quantification of Tau Load Using [F]AV1451 PET. *Molecular Imaging and Biology*, **2017**, 19, 963-971	3.8	31
569	7T T2-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 20-6	5.6	31
568	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. *Alzheimer's Research and Therapy*, **2017**, 9, 101	9	31
567	Young Alzheimer patients show distinct regional changes of oscillatory brain dynamics. *Neurobiology of Aging*, **2012**, 33, 1008.e25-31	5.6	31
566	A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2017**, 55, 521-537	4.3	31
565	ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. *Neurology*, **2020**, 95, e46-e58	6.5	30
564	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*, **2018**, 3, 463-472	3.4	30
563	SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. *Human Molecular Genetics*, **2014**, 23, 6644-58	5.6	30
562	Quantitation of brain tissue changes associated with white matter hyperintensities by diffusion-weighted and magnetization transfer imaging: the LADIS (Leukoaraiosis and Disability in the Elderly) study. *Journal of Magnetic Resonance Imaging*, **2009**, 29, 268-74	5.6	30
561	Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2016**, 5, 43-52	5.2	30
560	Centenarian controls increase variant effect sizes by an average twofold in an extreme case-extreme control analysis of Alzheimer's disease. *European Journal of Human Genetics*, **2019**, 27, 244-253	5.3	30

559	Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 563-572	5.2	30
558	Clinical phenotype, atrophy, and small vessel disease in 2 carriers with Alzheimer disease. *Neurology*, **2018**, 91, e1851-e1859	6.5	30
557	Global Prevalence of Young-Onset Dementia: A Systematic Review and Meta-analysis. *JAMA Neurology*, **2021**, 78, 1080-1090	17.2	30
556	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. *Neurobiology of Aging*, **2018**, 61, 75-81	5.6	29
555	The influence of co-morbidity and frailty on the clinical manifestation of patients with Alzheimer's disease. *Journal of Alzheimer's Disease*, **2014**, 42, 501-9	4.3	29
554	Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 9, 76-83	5.2	29
553	Distribution of APOE genotypes in a memory clinic cohort. *Dementia and Geriatric Cognitive Disorders*, **2008**, 25, 433-8	2.6	29
552	A clinical-radiological framework of the right temporal variant of frontotemporal dementia. *Brain*, **2020**, 143, 2831-2843	11.2	29
551	Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2015**, 47, 243-52	4.3	28
550	Amyloid and its association with default network integrity in Alzheimer's disease. *Human Brain Mapping*, **2014**, 35, 779-91	5.9	28
549	Diagnostic impact of CSF biomarkers in a local hospital memory clinic. *Dementia and Geriatric Cognitive Disorders*, **2010**, 29, 491-7	2.6	28
548	Amyloid-1Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project. *Frontiers in Aging Neuroscience*, **2019**, 11, 7	5.3	27
547	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. *Clinical Chemistry*, **2018**, 64, 927-937	5.5	27
546	Infratentorial abnormalities in vascular dementia. *Stroke*, **2006**, 37, 105-10	6.7	27
545	Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic Cohort: The SABRE Study. *Frontiers in Aging Neuroscience*, **2018**, 10, 279	5.3	27
544	New insights into the genetic etiology of Alzheimer's disease and related dementias.. *Nature Genetics*, **2022**,	36.3	27
543	Discordant amyloid-PET and CSF biomarkers and its clinical consequences. *Alzheimer's Research and Therapy*, **2019**, 11, 78	9	26
542	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. *Human Brain Mapping*, **2018**, 39, 3143-3151	5.9	26

541	Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study. *NeuroImage: Clinical*, **2015**, 9, 418-29	5.3	26
540	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. *Neurobiology of Aging*, **2018**, 61, 198-206	5.6	25
539	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. *Alzheimer's Research and Therapy*, **2018**, 10, 72	9	25
538	Quantitative regional validation of the visual rating scale for posterior cortical atrophy. *European Radiology*, **2014**, 24, 397-404	8	25
537	Magnetization transfer imaging of gray and white matter in mild cognitive impairment and Alzheimer's disease. *Neurobiology of Aging*, **2006**, 27, 1757-62	5.6	25
536	MRI measures and progression of cognitive decline in nondemented elderly attending a memory clinic. *International Journal of Geriatric Psychiatry*, **2005**, 20, 1060-6	3.9	25
535	Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline. *Frontiers in Psychiatry*, **2020**, 11, 585686	5	25
534	Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. *Alzheimer's and Dementia*, **2014**, 10, S299-305	1.2	24
533	Structural neuroimaging58-69		24
532	Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease. *International Journal of Geriatric Psychiatry*, **2008**, 23, 387-92	3.9	24
531	Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer's Disease in a Family with Several Generations of APOE-e4 Homozygosity. *Journal of Alzheimer's Disease*, **2017**, 56, 63-74	4.3	23
530	Alzheimer's disease risk variants modulate endophenotypes in mild cognitive impairment. *Alzheimer's and Dementia*, **2016**, 12, 872-81	1.2	23
529	Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. *Neurobiology of Aging*, **2014**, 35, 2665-2670	5.6	23
528	Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease. *Journal of Alzheimer's Disease*, **2010**, 20, 1083-90	4.3	23
527	Neuropsychological correlates of MRI measures in the continuum of cognitive decline at old age. *Dementia and Geriatric Cognitive Disorders*, **2005**, 20, 82-8	2.6	23
526	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. *Nature Communications*, **2021**, 12, 3417	17.4	23
525	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2016**, 51, 581-90	4.3	23
524	The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria. *Journal of Alzheimer's Disease*, **2017**, 60, 959-975	4.3	22

523	Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project. *Alzheimer's Research and Therapy*, **2019**, 11, 33	9	22
522	Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project. *Neurobiology of Aging*, **2019**, 79, 50-58	5.6	22
521	Long-Term Prognostic Implications of Previous Silent Myocardial Infarction in Patients Presenting With Acute Myocardial Infarction. *JACC: Cardiovascular Imaging*, **2018**, 11, 1773-1781	8.4	22
520	Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. *Journal of Alzheimer's Disease*, **2018**, 62, 1827-1839	4.3	22
519	Malnutrition and Risk of Structural Brain Changes Seen on Magnetic Resonance Imaging in Older Adults. *Journal of the American Geriatrics Society*, **2016**, 64, 2457-2463	5.6	22
518	Influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. *Neurobiology of Aging*, **2015**, 36, 1605.e13-20	5.6	22
517	Building a new paradigm for the early recognition of behavioral variant frontotemporal dementia: Late Onset Frontal Lobe Syndrome study. *American Journal of Geriatric Psychiatry*, **2014**, 22, 735-40	6.5	22
516	EEG functional connectivity and ApoE genotype in Alzheimer's disease and controls. *Clinical Neurophysiology*, **2008**, 119, 2727-32	4.3	22
515	Shifting paradigms in dementia: toward stratification of diagnosis and treatment using MRI. *Annals of the New York Academy of Sciences*, **2007**, 1097, 215-24	6.5	22
514	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. *Alzheimer's and Dementia*, **2017**, 13, 903-912	1.2	21
513	Diagnostic dilemmas in Alzheimer's disease: Room for shared decision making. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2017**, 3, 301-304	6	21
512	Detecting frontotemporal dementia syndromes using MRI biomarkers. *NeuroImage: Clinical*, **2019**, 22, 101711	5.3	21
511	The rest-activity rhythm and physical activity in early-onset dementia. *Alzheimer Disease and Associated Disorders*, **2015**, 29, 45-9	2.5	21
510	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. *Frontiers in Aging Neuroscience*, **2018**, 10, 111	5.3	21
509	Apraxia in mild cognitive impairment and Alzheimer's disease: validity and reliability of the Van Heugten test for apraxia. *Dementia and Geriatric Cognitive Disorders*, **2014**, 38, 55-64	2.6	21
508	Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology. *Journal of Alzheimer's Disease*, **2016**, 49, 927-43	4.3	21
507	Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease. *JMIR Formative Research*, **2019**, 3, e13417	2.5	21
506	Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. *The Lancet Healthy Longevity*, **2021**, 2, e87-e95	9.5	21

505	Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. *Nature Communications*, **2019**, 10, 2240	17.4	20
504	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. *Alzheimer's Research and Therapy*, **2017**, 9, 73	9	20
503	Comparison of simplified parametric methods for visual interpretation of 11C-Pittsburgh compound-B PET images. *Journal of Nuclear Medicine*, **2014**, 55, 1305-7	8.9	20
502	The structure of the geriatric depressed brain and response to electroconvulsive therapy. *Psychiatry Research - Neuroimaging*, **2014**, 222, 1-9	2.9	20
501	Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. *Alzheimer's and Dementia*, **2013**, 9, 276-83	1.2	20
500	Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP) synthesis in Alzheimer's disease with the use of index values. *Journal of Alzheimer's Disease*, **2010**, 22, 1073-9	4.3	20
499	Multitracer model for staging cortical amyloid deposition using PET imaging. *Neurology*, **2020**, 95, e1538-e1553	6.5	20
498	Sex differences in CSF biomarkers vary by Alzheimer disease stage and ε4 genotype. *Neurology*, **2020**, 95, e2378-e2388	6.5	20
497	Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset. *Scientific Reports*, **2019**, 9, 16742	4.9	20
496	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [F]-Flutemetamol PET Scan Result. *Frontiers in Aging Neuroscience*, **2018**, 10, 409	5.3	20
495	Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2018**, 61, 309-320	4.3	19
494	Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population. *Journal of Alzheimer's Disease*, **2013**, 36, 79-85	4.3	19
493	Progression to dementia in memory clinic patients without dementia: a latent profile analysis. *Neurology*, **2013**, 81, 1342-9	6.5	19
492	Neuropsychological predictors of dementia in a three-year follow-up period: data from the LADIS study. *Dementia and Geriatric Cognitive Disorders*, **2010**, 29, 325-34	2.6	19
491	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies. *Alzheimer's and Dementia*, **2019**, 15, 185-193	1.2	19
490	CSF ApoE predicts clinical progression in nondemented APOEε4 carriers. *Neurobiology of Aging*, **2017**, 57, 186-194	5.6	18
489	Clinicians' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2017**, 3, 305-313	6	18
488	Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach. *American Journal of Geriatric Psychiatry*, **2015**, 23, 1056-66	6.5	18

487	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. *Acta Neuropathologica*, **2020**, 139, 1025-1044	14.3	18
486	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. *Neurobiology of Aging*, **2020**, 89, 99-107	5.6	18
485	Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. *Neurobiology of Aging*, **2018**, 61, 238-244	5.6	18
484	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. *Frontiers in Aging Neuroscience*, **2018**, 10, 67	5.3	18
483	Validation of the automated method VIENA: an accurate, precise, and robust measure of ventricular enlargement. *Human Brain Mapping*, **2014**, 35, 1101-10	5.9	18
482	Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia. *BMC Neuroscience*, **2012**, 13, 85	3.2	18
481	A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers. *Alzheimer's and Dementia*, **2013**, 9, 262-8	1.2	18
480	Associations between magnetic resonance imaging measures and neuropsychological impairment in early and late onset alzheimer's disease. *Journal of Alzheimer's Disease*, **2013**, 35, 169-78	4.3	18
479	Clinical characteristics of patients with frontotemporal dementia with and without lobar atrophy on MRI. *Alzheimer Disease and Associated Disorders*, **2010**, 24, 242-7	2.5	18
478	Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*, **2008**, 26, 522-7	2.6	18
477	Lobar distribution of changes in gray matter and white matter in memory clinic patients: detected using magnetization transfer imaging. *American Journal of Neuroradiology*, **2007**, 28, 1938-42	4.4	18
476	Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease. *Scientific Reports*, **2021**, 11, 9736	4.9	18
475	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. *NeuroImage: Clinical*, **2018**, 19, 625-632	5.3	18
474	Effect of long-term storage in biobanks on cerebrospinal fluid biomarker A□T-tau, and P-tau values. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 8, 45-50	5.2	17
473	Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 8, 139-146	5.2	17
472	Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2019**, 70, 389-397	4.3	17
471	The metabolic syndrome in a memory clinic population: relation with clinical profile and prognosis. *Journal of the Neurological Sciences*, **2015**, 351, 18-23	3.2	17
470	Disturbed phase relations in white matter hyperintensity based vascular dementia: an EEG directed connectivity study. *Clinical Neurophysiology*, **2015**, 126, 497-504	4.3	17

469	Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. *Annals of Clinical and Translational Neurology*, **2018**, 5, 1037-1047	5.3	17
468	Directional information flow in patients with Alzheimer's disease. A source-space resting-state MEG study. *NeuroImage: Clinical*, **2017**, 15, 673-681	5.3	17
467	Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples. *Clinical Chemistry and Laboratory Medicine*, **2011**, 50, 61-5	5.9	17
466	Episodic memory and the medial temporal lobe: not all it seems. Evidence from the temporal variants of frontotemporal dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2012**, 83, 1145-8	5.5	17
465	Clinical aspects of microbleeds in Alzheimer's disease. *Journal of the Neurological Sciences*, **2012**, 322, 56-8	3.2	17
464	Increase in cerebrospinal fluid F2-isoprostanes is related to cognitive decline in APOE ε4 carriers. *Journal of Alzheimer's Disease*, **2013**, 36, 563-70	4.3	17
463	EEG abnormalities are associated with different cognitive profiles in Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*, **2011**, 31, 1-6	2.6	17
462	PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases. *Alzheimer's Research and Therapy*, **2019**, 11, 100	9	17
461	Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. *Human Brain Mapping*, **2019**, 40, 638-651	5.9	17
460	Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project. *Nutrients*, **2019**, 11,	6.7	16
459	Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. *Current Alzheimer Research*, **2019**, 16, 91-101	3	16
458	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. *Molecular Neurodegeneration*, **2020**, 15, 36	19	16
457	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. *Neurobiology of Aging*, **2019**, 84, 225-234	5.6	16
456	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. *Alzheimer's and Dementia*, **2020**, 16, 1457-1468	1.2	16
455	Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy. *Journal of Alzheimer's Disease*, **2015**, 44, 153-62	4.3	15
454	Time Trend in Persistent Cognitive Decline: Results From the Longitudinal Aging Study Amsterdam. *Journals of Gerontology - Series B Psychological Sciences and Social Sciences*, **2018**, 73, S57-S64	4.6	15
453	European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials. *Alzheimer's and Dementia*, **2018**, 14, 837-842	1.2	15
452	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. *Journal of Psychiatric Research*, **2018**, 104, 183-191	5.2	15

451	Quantification of [F]florbetapir: A test-retest tracer kinetic modelling study. *Journal of Cerebral Blood Flow and Metabolism*, **2019**, 39, 2172-2180	7.3	15
450	VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	15
449	Dysglycemia, brain volume and vascular lesions on MRI in a memory clinic population. *Journal of Diabetes and Its Complications*, **2014**, 28, 85-90	3.2	15
448	No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds. *Journal of Cerebral Blood Flow and Metabolism*, **2012**, 32, 1468-71	7.3	15
447	Usefulness of longitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders. *Clinical Chemistry*, **2006**, 52, 1604-6	5.5	15
446	Web-Based Multidomain Lifestyle Programs for Brain Health: Comprehensive Overview and Meta-Analysis. *JMIR Mental Health*, **2019**, 6, e12104	6	15
445	Low normal cerebrospinal fluid Aβ42 levels predict clinical progression in nondemented subjects. *Annals of Neurology*, **2017**, 81, 749-753	9.4	14
444	Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study. *Alzheimer's Research and Therapy*, **2019**, 11, 25	9	14
443	Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. *Neurology*, **2019**, 92, e1558-e1566	6.5	14
442	Alzheimer's disease patients not carrying the apolipoprotein E ε4 allele show more severe slowing of oscillatory brain activity. *Neurobiology of Aging*, **2013**, 34, 2158-63	5.6	14
441	Translational research in genomics of Alzheimer's disease: a review of current practice and future perspectives. *Journal of Alzheimer's Disease*, **2010**, 20, 967-80	4.3	14
440	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. *Alzheimer's Research and Therapy*, **2021**, 13, 198	9	14
439	Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. *NeuroImage: Clinical*, **2019**, 22, 101786	5.3	13
438	Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. *Alzheimer's Research and Therapy*, **2018**, 10, 23	9	13
437	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. *Alzheimer's Research and Therapy*, **2018**, 10, 58	9	13
436	The Impact of Frailty and Comorbidity on Institutionalization and Mortality in Persons With Dementia: A Prospective Cohort Study. *Journal of the American Medical Directors Association*, **2019**, 20, 165-170.e2	5.9	13
435	Clinician-patient communication during the diagnostic workup: The ABIDE project. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 520-528	5.2	13
434	Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study. *Journal of Neurology*, **2014**, 261, 1160-9	5.5	13

433	Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology. *Acta Neuropathologica Communications*, **2014**, 2, 79	7.3	13
432	Actigraphic motor activity in mild cognitive impairment patients carrying out short functional activity tasks: comparison between mild cognitive impairment with and without depressive symptoms. *Journal of Alzheimer's Disease*, **2014**, 40, 869-75	4.3	13
431	Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia. *Alzheimer's and Dementia*, **2013**, 9, 269-75	1.2	13
430	Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements. *Clinical Chemistry and Laboratory Medicine*, **2008**, 46, 1300-4	5.9	13
429	Detection of contactin-2 in cerebrospinal fluid (CSF) of patients with Alzheimer's disease using Fluorescence Correlation Spectroscopy (FCS). *Clinical Biochemistry*, **2017**, 50, 1061-1066	3.5	13
428	Test-retest repeatability of [F]Flortaucipir PET in Alzheimer's disease and cognitively normal individuals. *Journal of Cerebral Blood Flow and Metabolism*, **2020**, 40, 2464-2474	7.3	13
427	Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression. *Movement Disorders*, **2020**, 35, 859-867	7	13
426	Design of the ExCersion-VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2017**, 3, 157-165	6	12
425	ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly. *Neurobiology of Aging*, **2019**, 79, 101-109	5.6	12
424	The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum. *American Journal of Geriatric Psychiatry*, **2020**, 28, 735-744	6.5	12
423	Pseudo-healthy Image Synthesis for White Matter Lesion Segmentation. *Lecture Notes in Computer Science*, **2016**, 87-96	0.9	12
422	Clinical heterogeneity in familial Alzheimer's disease. *Lancet Neurology, The*, **2016**, 15, 1296-1298	24.1	12
421	Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease. *Alzheimer's Research and Therapy*, **2018**, 10, 52	9	12
420	Evaluating combinations of diagnostic tests to discriminate different dementia types. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 509-518	5.2	12
419	Frequent Cognitive Impairment in Patients With Disorders Along the Heart-Brain Axis. *Stroke*, **2019**, 50, 3369-3375	6.7	12
418	Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. *Journal of Alzheimer's Disease*, **2016**, 50, 261-70	4.3	12
417	Study protocol: EXERcise and cognition in sedentary adults with early-ONset dementia (EXERCISE-ON). *BMC Neurology*, **2012**, 12, 75	3.1	12
416	Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. *Journal of the American Medical Directors Association*, **2020**, 21, 1513.e1-1513.e17	5.9	12

415	A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands. *BMC Neurology*, **2016**, 16, 242	3.1	12
414	White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-β. *Journal of Alzheimer's Disease*, **2017**, 55, 333-342	4.3	12
413	Nature and implications of sex differences in AD pathology. *Nature Reviews Neurology*, **2019**, 15, 6-8	15	12
412	ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics. *Alzheimer's Research and Therapy*, **2019**, 11, 77	9	11
411	High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. *Neuropsychologia*, **2019**, 131, 184-192	3.2	11
410	Automatically computed rating scales from MRI for patients with cognitive disorders. *European Radiology*, **2019**, 29, 4937-4947	8	11
409	A Suboptimal Diet is Associated with Poorer Cognition: The NUDAD Project. *Nutrients*, **2020**, 12,	6.7	11
408	Regional [F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 2866-2878	8.8	11
407	Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2018**, 64, 631-642	4.3	11
406	Orthostatic Hypotension: An Important Risk Factor for Clinical Progression to Mild Cognitive Impairment or Dementia. The Amsterdam Dementia Cohort. *Journal of Alzheimer's Disease*, **2019**, 71, 317-325	4.3	11
405	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. *Alzheimer's and Dementia*, **2019**, 15, 1458-1467	1.2	11
404	Hypertensive Disorders of Pregnancy Appear Not to Be Associated with Alzheimer's Disease Later in Life. *Dementia and Geriatric Cognitive Disorders Extra*, **2015**, 5, 375-85	2.5	11
403	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2015**, 46, 889-99	4.3	11
402	Carotid and basilar artery wall shear stress in Alzheimer's disease and mild cognitive impairment. *Dementia and Geriatric Cognitive Disorders*, **2009**, 28, 220-4	2.6	11
401	Improving the accuracy and precision of cognitive testing in mild dementia. *Journal of the International Neuropsychological Society*, **2012**, 18, 314-22	3.1	11
400	Communicating uncertainties when disclosing diagnostic test results for (Alzheimer's) dementia in the memory clinic: The ABIDE project. *Health Expectations*, **2020**, 23, 52-62	3.7	11
399	Olfactory and gustatory functioning and food preferences of patients with Alzheimer's disease and mild cognitive impairment compared to controls: the NUDAD project. *Journal of Neurology*, **2020**, 267, 144-152	5.5	11
398	Multiple diagnostic tests are needed to assess multiple causes of dementia. *Archives of Neurology*, **2006**, 63, 144-6		11

397	Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests. *Journal of Alzheimer's Disease*, **2017**, 56, 249-259	4.3	10
396	Gray matter T1-w/T2-w ratios are higher in Alzheimer's disease. *Human Brain Mapping*, **2019**, 40, 3900-3909	5.9	10
395	Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 3165-3175	8.8	10
394	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2020**, 73, 1585-1595	4.3	10
393	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. *Neurobiology of Aging*, **2017**, 49, 214.e13-214.e15	5.6	10
392	Use of laboratory and imaging investigations in dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2005**, 76 Suppl 5, v45-52	5.5	10
391	Amyloid-□misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. *Alzheimer's Research and Therapy*, **2020**, 12, 169	9	10
390	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services-part 2 of 6. *Alzheimer's Research and Therapy*, **2021**, 13, 169	9	10
389	Immune response and endocytosis pathways are associated with the resilience against Alzheimer's disease. *Translational Psychiatry*, **2020**, 10, 332	8.6	10
388	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. *Journal of the International Neuropsychological Society*, **2021**, 27, 426-438	3.1	10
387	Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCe Project. *Nutrients*, **2019**, 11,	6.7	9
386	Standard biobanking conditions prevent evaporation of body fluid samples. *Clinica Chimica Acta*, **2015**, 442, 141-5	6.2	9
385	Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimer's Disease and Vascular Dementia. *Antioxidants*, **2020**, 9,	7.1	9
384	Cortical phase changes measured using 7-T MRI in subjects with subjective cognitive impairment, and their association with cognitive function. *NMR in Biomedicine*, **2016**, 29, 1289-94	4.4	9
383	Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression. *Journal of Alzheimer's Disease*, **2018**, 65, 1029-1039	4.3	9
382	Survival in memory clinic cohort is short, even in young-onset dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 726-728	5.5	9
381	Lumbar puncture in patients with neurologic conditions. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 8, 108-110	5.2	9
380	Progression from MCI to AD: predictive value of CSF A□42 is modified by APOE genotype. *Neurobiology of Aging*, **2011**, 32, 1372-8	5.6	9

379	Association between vitamin B6 and white matter hyperintensities in patients with Alzheimer's disease not mediated by homocysteine metabolism. *Journal of the American Geriatrics Society*, **2007**, 55, 956-8	5.6	9
378	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. *JAMA Neurology*, **2022**,	17.2	9
377	Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: the NUDAD project. *Alzheimer's Research and Therapy*, **2020**, 12, 116	9	9
376	Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. *Neurology*, **2020**, 95, e1672-e1685	6.5	9
375	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. *Alzheimer's and Dementia*, **2021**, 17, 1189-1204	1.2	9
374	Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies. *Neurology*, **2021**, 97, e930-e940	6.5	9
373	Dietary patterns are related to cognitive functioning in elderly enriched with individuals at increased risk for Alzheimer's disease. *European Journal of Nutrition*, **2021**, 60, 849-860	5.2	9
372	Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer's disease. *NeuroImage: Clinical*, **2021**, 31, 102712	5.3	9
371	Clinicians' communication with patients receiving a MCI diagnosis: The ABIDE project. *PLoS ONE*, **2020**, 15, e0227282	3.7	8
370	Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. *Dementia and Geriatric Cognitive Disorders*, **2016**, 41, 16-26	2.6	8
369	Energy and Protein Intake of Alzheimer's Disease Patients Compared to Cognitively Normal Controls: Systematic Review. *Journal of the American Medical Directors Association*, **2019**, 20, 14-21	5.9	8
368	Pre-analytical stability of novel cerebrospinal fluid biomarkers. *Clinica Chimica Acta*, **2019**, 497, 204-211	6.2	8
367	Glycemia and levels of cerebrospinal fluid amyloid and tau in patients attending a memory clinic. *Journal of the American Geriatrics Society*, **2010**, 58, 1318-21	5.6	8
366	Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. *Neurology*, **2021**, 96, e2673-e2684	6.5	8
365	The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. *Journal of Alzheimer's Disease*, **2019**, 68, 311-322	4.3	8
364	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 1-9	5.2	8
363	Computer-assisted prediction of clinical progression in the earliest stages of AD. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 726-736	5.2	8
362	Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations. *Neurology*, **2021**, 97, e1276-e1287	6.5	8

361	Wishes and preferences for an online lifestyle program for brain health-A mixed methods study. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2018**, 4, 141-149	6	7
360	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. *European Journal of Nuclear Medicine and Molecular Imaging*, **2014**, 41, 1190-8	8.8	7
359	Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort. *Journal of Neurology*, **2014**, 261, 2085-92	5.5	7
358	Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion–symptom mapping study. *Journal of Psychiatry and Neuroscience*, **2019**, 44, E1-E10	4.5	7
357	Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. *Neurobiology of Aging*, **2020**, 94, 71-80	5.6	7
356	Brain amyloid – cerebral small vessel disease, and cognition: A memory clinic study. *Neurology*, **2020**, 95, e2845-e2853	6.5	7
355	Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods: A Systematic Review and Meta-analysis. *Neurology*, **2021**, 97, 474-488	6.5	7
354	Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results. *Alzheimer's Research and Therapy*, **2021**, 13, 53	9	7
353	Added value of amyloid PET in individualized risk predictions for MCI patients. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 529-537	5.2	6
352	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. *Journal of Neurology*, **2019**, 266, 2535-2545	5.5	6
351	Cerebral atrophy in elderly with subjective memory complaints. *Journal of Magnetic Resonance Imaging*, **2013**, 38, 358-64	5.6	6
350	Frontal lobe damage and thalamic volume changes. *NeuroReport*, **2000**, 11, 3039-41	1.7	6
349	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services-part 1 of 6. *Alzheimer's Research and Therapy*, **2021**, 13, 168	9	6
348	Methylphenidate and galantamine in patients with vascular cognitive impairment-the proof-of-principle study STREAM-VCI. *Alzheimer's Research and Therapy*, **2020**, 12, 10	9	6
347	Identifying a task-invariant cognitive reserve network using task potency. *NeuroImage*, **2020**, 210, 116593	7.9	6
346	Contribution of Gut Microbiota to Immunological Changes in Alzheimer's Disease. *Frontiers in Immunology*, **2021**, 12, 683068	8.4	6
345	Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status. *Alzheimer's Research and Therapy*, **2021**, 13, 133	9	6
344	Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies. *Alzheimer's Research and Therapy*, **2020**, 12, 44	9	6

343	Classification of negative and positive F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 721-728	8.8	6
342	Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study. *NeuroImage: Clinical*, **2020**, 28, 102504	5.3	5
341	Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project. *Journal of the American Medical Directors Association*, **2020**,	5.9	5
340	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. *Alzheimer's Research and Therapy*, **2020**, 12, 138	9	5
339	Microbleeds are associated with depressive symptoms in Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 112-120	5.2	5
338	Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. *Alzheimer's Research and Therapy*, **2019**, 11, 83	9	5
337	A novel CCM2 variant in a family with non-progressive cognitive complaints and cerebral microbleeds. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*, **2017**, 174, 220-226	3.5	5
336	The effect of APOE genotype on clinical phenotype in Alzheimer disease. *Neurology*, **2007**, 68, 624; author reply 624	6.5	5
335	Dementia risk communication. A user manual for Brain Health Services-part 3 of 6. *Alzheimer's Research and Therapy*, **2021**, 13, 170	9	5
334	Why Is Amyloid-PET Requested After Performing CSF Biomarkers?. *Journal of Alzheimer's Disease*, **2020**, 73, 559-569	4.3	5
333	Cerebral blood flow and cognitive functioning in patients with disorders along the heart-brain axis: Cerebral blood flow and the heart-brain axis. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2020**, 6, e12034	6	5
332	Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12063	5.2	5
331	Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid. *Journal of Alzheimer's Disease*, **2016**, 53, 107-16	4.3	5
330	Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. *Alzheimer's Research and Therapy*, **2021**, 13, 2	9	5
329	The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series. *Journal of Alzheimer's Disease*, **2021**, 79, 1195-1201	4.3	5
328	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2157-2168	8.8	5
327	How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. *Journal of Alzheimer's Disease*, **2019**, 68, 1273-1286	4.3	4
326	CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE ε4 carriers. *Scientific Reports*, **2020**, 10, 8233	4.9	4

325	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. *Journal of Alzheimer's Disease*, **2020**, 76, 1061-1070	4.3	4
324	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. *PLoS ONE*, **2020**, 15, e0226784	3.7	4
323	Assessing the Pre-Analytical Stability of Small-Molecule Metabolites in Cerebrospinal Fluid Using Direct-Infusion Metabolomics. *Metabolites*, **2019**, 9,	5.6	4
322	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2019**, 5, 492-500	6	4
321	[O2□12□3]: DURATION OF ALZHEIMER's DISEASE IN THE PRECLINICAL, PRODROMAL AND DEMENTIA STAGE: A MULTI-STATE MODEL ANALYSIS **2017**, 13, P585-P586		4
320	Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease. *Neurology*, **2003**, 60, 1558; author reply 1558-9	6.5	4
319	Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review.. *Alzheimer's Research and Therapy*, **2022**, 14, 31	9	4
318	Profound regional spectral, connectivity, and network changes reflect visual deficits in posterior cortical atrophy: an EEG study. *Neurobiology of Aging*, **2020**, 96, 1-11	5.6	4
317	P4-179: MEG Cross-Frequency Analysis in Patients With Alzheimer□s Disease **2016**, 12, P1087-P1088		4
316	Combinations of Service Use Types of People With Early Cognitive Disorders. *Journal of the American Medical Directors Association*, **2016**, 17, 620-5	5.9	4
315	Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2016**, 2, 233-240	6	4
314	Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease. *Neurobiology of Aging*, **2019**, 73, 230.e9-230.e17	5.6	4
313	The protective gene dose effect of the APOE □2 allele on gray matter volume in cognitively unimpaired individuals. *Alzheimer's and Dementia*, **2021**,	1.2	4
312	Using cerebrospinal fluid amyloid-beta(1-42) in the memory clinic: Concordance with PET and use of biomarker ratios across immunoassays. *Alzheimer's and Dementia*, **2020**, 16, e045128	1.2	3
311	Non-memory cognitive symptom development in Alzheimer's disease. *European Journal of Neurology*, **2020**, 27, 995-1002	6	3
310	[P2□052]: THE DUTCH BRAIN HEALTH REGISTRY: OPTIMIZING RECRUITMENT FOR DEMENTIA RESEARCH **2017**, 13, P624-P624		3
309	Neurological signs in relation to white matter hyperintensity volumes in memory clinic patients. *Dementia and Geriatric Cognitive Disorders*, **2010**, 29, 301-8	2.6	3
308	Knowing the natural course of biomarkers in AD: longitudinal MRI, CSF and PET data. *Journal of Nutrition, Health and Aging*, **2009**, 13, 353-5	5.2	3

307	Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. *JMIR Research Protocols*, **2018**, 7, e80	2	3
306	Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. *Brain Communications*, **2020**, 2, fcaa177	4.5	3
305	Comorbid amyloid-β pathology affects clinical and imaging features in VCD. *Alzheimer's and Dementia*, **2020**, 16, 354-364	1.2	3
304	cCOG: A web-based cognitive test tool for detecting neurodegenerative disorders. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12083	5.2	3
303	Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies. *Biomolecules*, **2020**, 10,	5.9	3
302	[F]Flortaucipir PET Across Various Mutations in Presymptomatic and Symptomatic Carriers. *Neurology*, **2021**, 97, e1017-e1030	6.5	3
301	Repeatability of parametric methods for [F]florbetapir imaging in Alzheimer's disease and healthy controls: A test-retest study. *Journal of Cerebral Blood Flow and Metabolism*, **2021**, 41, 569-578	7.3	3
300	Hypertensive Exposure Markers by MRI in Relation to Cerebral Small Vessel Disease and Cognitive Impairment. *JACC: Cardiovascular Imaging*, **2021**, 14, 176-185	8.4	3
299	Circulating metabolites are associated with brain atrophy and white matter hyperintensities. *Alzheimer's and Dementia*, **2021**, 17, 205-214	1.2	3
298	Grey zone amyloid burden affects memory function: the SCIENCe project. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 747-756	8.8	3
297	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. *NeuroImage: Clinical*, **2021**, 30, 102660	5.3	3
296	Amyloid-β cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. *Annals of Clinical and Translational Neurology*, **2021**, 8, 348-358	5.3	3
295	Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. *Journal of Alzheimer's Disease*, **2021**, 83, 269-279	4.3	3
294	What patients want to know, and what we actually tell them: The ABIDE project. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2020**, 6, e12113	6	3
293	IC-P-013: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA **2014**, 10, P14-P14		2
292	[P1–243]: ALPHA-SYNUCLEIN SPECIES AS POTENTIAL CSF BIOMARKERS FOR DEMENTIA WITH LEWY BODIES **2017**, 13, P338-P338		2
291	[P1–375]: DATA-DRIVEN DIAGNOSIS OF DEMENTIA DISORDERS: THE PREDICTND VALIDATION STUDY **2017**, 13, P405-P407		2
290	IC-01-04: Diagnostic impact of [18F]flutemetamol amyloid imaging in young-onset dementia **2015**, 11, P3-P4		2

289	F2-03-04: Genetic risk factors for posterior cortical atrophy **2015**, 11, P168-P169		2
288	Prevalence and severity of microbleeds in a memory clinic setting. *Neurology*, **2007**, 68, 391; author reply 391	6.5	2
287	Polygenic Risk Score of Longevity Predicts Longer Survival Across an Age Continuum. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2021**, 76, 750-759	6.4	2
286	Reply to "Usefulness of Plasma Amyloid as Prescreener of the Earliest Alzheimer Pathological Changes Depends on the Study Population". *Annals of Neurology*, **2020**, 87, 155	9.4	2
285	Hippocampal [F]flortaucipir BP corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. *NeuroImage: Clinical*, **2020**, 25, 102113	5.3	2
284	Small vessel disease lesion type and brain atrophy: The role of co-occurring amyloid. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12060	5.2	2
283	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. *Journal of Alzheimer's Disease*, **2021**, 82, 381-390	4.3	2
282	Assessing the Views of Professionals, Patients, and Care Partners Concerning the Use of Computer Tools in Memory Clinics: International Survey Study. *JMIR Formative Research*, **2021**, 5, e31053	2.5	2
281	P4-224: Alzheimer's Disease Patients With Osas History Have Higher CSF Tau Levels **2016**, 12, P1115-P1115		2
280	High occurrence of transportation and logistics occupations among vascular dementia patients: an observational study. *Alzheimer's Research and Therapy*, **2019**, 11, 112	9	2
279	Risk of dementia in ε4 carriers is mitigated by a polygenic risk score. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12229	5.2	2
278	Effect of Shortening the Scan Duration on Quantitative Accuracy of [F]Flortaucipir Studies. *Molecular Imaging and Biology*, **2021**, 23, 604-613	3.8	2
277	IC-P-192: DISEASE-STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE **2018**, 14, P158-P160		2
276	Diagnostiek van dementie: praktijkvariatie in Nederlandse geheugenpoliklinieken. *Neuropraxis*, **2018**, 22, 137-146	0	2
275	Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia. *Neurobiology of Aging*, **2021**, 107, 1-10	5.6	2
274	BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCe project. *Neurobiology of Aging*, **2021**, 108, 146-154	5.6	2
273	Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial.. *Alzheimer's and Dementia*, **2022**,	1.2	2
272	Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies. *Alzheimer's and Dementia*, **2020**, 16, e041048	1.2	1

271	The evolution of neuropsychiatric symptoms in atypical variants of Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, e045236	1.2	1
270	Prediction of amyloid PET status using the LUMIPULSE G β-amyloid ratio (1-42/1-40). *Alzheimer's and Dementia*, **2020**, 16, e046006	1.2	1
269	O5-07-02: Personalized Risk Estimates for Mci Patients: Taking Biomarkers Into the Clinic **2016**, 12, P393-P393		1
268	P1-258: CORTICAL PHASE CHANGES AT 7T MRI IN SUBJECTIVE COGNITIVE IMPAIRMENT AND THEIR ASSOCIATION WITH COGNITIVE FUNCTION **2014**, 10, P402-P402		1
267	P1-135: DIRECTED ANTERIOR-TO-POSTERIOR COMMUNICATION IN THE BRAIN IS REVERSED IN DEMENTIA WITH LEWY BODIES AND IS RELATED TO ATTENTION DEFICITS **2014**, 10, P349-P349		1
266	O4-01-05: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS **2014**, 10, P250-P250		1
265	IC-P-109: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY: A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER DISEASE **2014**, 10, P61-P61		1
264	O4-01-01: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA **2014**, 10, P248-P248		1
263	F5□1□2: CSF biomarkers and APOE genotype as predictors of clinical progression in patients with subjective complaints **2013**, 9, P824-P824		1
262	[P3□86]: COMPUTED RATING SCALES FOR COGNITIVE DISORDERS FROM MRI **2017**, 13, P1108-P1108		1
261	[IC-P-005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID-□AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS **2017**, 13, P13-P14		1
260	[P4□25]: DATA-DRIVEN TAU-PET COVARIANCE NETWORKS ENHANCE PREDICTION OF RETROSPECTIVE COGNITIVE CHANGE IN ALZHEIMER's DISEASE **2017**, 13, P1548-P1549		1
259	P4-089: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease **2015**, 11, P806-P807		1
258	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study **2015**, 11, P297-P297		1
257	F2-03-02: Early onset APOE-e4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains **2015**, 11, P168-P168		1
256	O3-14-04: The relation between eeg spectral analysis and clinical progression in non-demented, amyloid-positive subjects **2015**, 11, P255-P256		1
255	Hippocampal volume and cognition in geriatric depression. *Biological Psychiatry*, **2001**, 50, 68-9	7.9	1
254	Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease.. *European Journal of Nuclear Medicine and Molecular Imaging*, **2022**, 1	8.8	1

253	Development and Usability of ADappt: Web-Based Tool to Support Clinicians, Patients, and Caregivers in the Diagnosis of Mild Cognitive Impairment and Alzheimer Disease (Preprint)		1
252	A Semi-supervised Large Margin Algorithm for White Matter Hyperintensity Segmentation. *Lecture Notes in Computer Science*, **2016**, 104-112	0.9	1
251	Exome sequencing identifies rare damaging variants in the ATP8B4 and ABCA1 genes as novel risk factors for Alzheimer□ Disease		1
250	Data-driven detection of latent atrophy factors related to phenotypical variants of posterior cortical atrophy		1
249	Differential Dementia Diagnosis on Incomplete Data with Latent Trees. *Lecture Notes in Computer Science*, **2016**, 44-52	0.9	1
248	Prediction of poor clinical outcome in vascular cognitive impairment: TRACE-VCI study. *Alzheimer□s and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12077	5.2	1
247	The natural history of primary progressive aphasia: beyond aphasia. *Journal of Neurology*, **2021**, 1	5.5	1
246	P4-153: Subjective Cognitive Decline and Progression to Dementia Due to AD and Non-AD in Memory Clinic and Community-Based Cohorts **2016**, 12, P1073-P1073		1
245	IC-P-092: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY **2018**, 14, P76-P79		1
244	P4-106: DECLINE IN GREY MATTER CONNECTIVITY OVER TIME IS RELATED TO CLINICAL PROGRESSION IN MCI DUE TO AD **2018**, 14, P1479-P1479		1
243	P1-602: DUTCH ONLINE REGISTRY FOR RECRUITMENT OF PARTICIPANTS FOR DEMENTIA STUDIES: HERSENONDERZOEK.NL AND BRAIN HEALTH REGISTRY **2018**, 14, P569-P570		1
242	Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis?. *Alzheimer□s and Dementia: Translational Research and Clinical Interventions*, **2021**, 7, e12189	6	1
241	The Cognitive Online Self-Test Amsterdam (COST-A): Establishing norm scores in a community-dwelling population. *Alzheimer□s and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12234	5.2	1
240	The Effect of Alzheimer's Disease-Associated Genetic Variants on Longevity.. *Frontiers in Genetics*, **2021**, 12, 748781	4.5	1
239	Development of an ultrasensitive multiplex assay for simultaneous detection of A□1-42, A□1-40, GFAP and NF-L in blood. *Alzheimer□s and Dementia*, **2020**, 16, e043506	1.2	0
238	A mixed-methods approach to establish clinically meaningful categories of impairment in instrumental activities of daily living. *Alzheimer□s and Dementia*, **2020**, 16, e045693	1.2	0
237	Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis. *Alzheimer□s and Dementia*, **2020**, 16, e045829	1.2	0
236	Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. *Journal of the American Medical Directors Association*, **2020**, 21, 1436-1438	5.9	0

235	IC-P-076: WHITE MATTER HYPERINTENSITIES PREDICT MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN PATIENTS WITH SUBJECTIVE COGNITIVE COMPLAINTS **2014**, 10, P42-P43		0
234	P3-096: MAGNETOENCEPHALOGRAPHY IN DEMENTIA: THE STATE OF THE ART **2014**, 10, P663-P663		0
233	Can lumbar puncture help to identify patients with incipient Alzheimer's disease?. *Nature Clinical Practice Neurology*, **2006**, 2, 530-1		0
232	Everyday Functioning in a Community-Based Volunteer Population: Differences Between Participant- and Study Partner-Report.. *Frontiers in Aging Neuroscience*, **2021**, 13, 761932	5.3	0
231	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline.. *Brain Communications*, **2022**, 4, fcac026	4.5	0
230	An Operational Definition of 'Abnormal Cognition' to Optimize the Prediction of Progression to Dementia: What Are Optimal Cut-Off Points for Univariate and Multivariate Normative Comparisons?. *Journal of Alzheimer's Disease*, **2020**, 77, 1693-1703	4.3	0
229	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2020**, 12, e12120	5.2	0
228	IC-P-153: Thinner Cortical Thickness in Patients With Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function **2016**, 12, P113-P114		0
227	Biomarker testing in MCI patients-deciding who to test. *Alzheimer's Research and Therapy*, **2021**, 13, 14	9	0
226	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. *Translational Psychiatry*, **2021**, 11, 451	8.6	0
225	Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups. *NeuroImage: Clinical*, **2021**, 31, 102725	5.3	0
224	[IC-P-130]: MRI-BASED CLASSIFICATION ACCURACY OF DEMENTIA TYPE IS DETERMINED BY MRI MODALITY **2017**, 13, P98-P99		
223	[P1‐092]: AUTOMATED SELECTION OF MULTIMODAL MRI BIOMARKERS FOR DIAGNOSIS OF DEMENTIA **2017**, 13, P417-P418		
222	Improving patient care through a national memory clinic network. *Alzheimer's and Dementia*, **2020**, 16, e039017	1.2	
221	Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort. *Alzheimer's and Dementia*, **2020**, 16, e040152	1.2	
220	Determinants of cognitive decline and dementia in stage 2: The SCIENCe project. *Alzheimer's and Dementia*, **2020**, 16, e040263	1.2	
219	Functional interpretation of genetic risk loci for dementia using a protein quantitative trait loci (pQTLs) approach in cerebrospinal fluid. *Alzheimer's and Dementia*, **2020**, 16, e040774	1.2	
218	Amyloid-β deposition in cognitively normal oldest-old is associated with cortical thinning and faster memory decline. *Alzheimer's and Dementia*, **2020**, 16, e040991	1.2	

217	Single-cell profiling of circulating and brain-resident immune cells in a mouse model for amyloidosis and in aged mice. *Alzheimer's and Dementia*, **2020**, 16, e041789	1.2
216	Polygenic risk score for Alzheimer's disease is related to amyloid positivity in subjective cognitive decline: The SCIENCe project. *Alzheimer's and Dementia*, **2020**, 16, e042116	1.2
215	Biomarker testing in MCI patients: Deciding who to tap. *Alzheimer's and Dementia*, **2020**, 16, e042735	1.2
214	Amyloid-β deposition in cognitively normal oldest-old is associated with cortical thinning and faster memory decline. *Alzheimer's and Dementia*, **2020**, 16, e042768	1.2
213	Gray matter atrophy, but not vascular brain injury is related to cognitive impairment in patients with heart failure. *Alzheimer's and Dementia*, **2020**, 16, e042892	1.2
212	Dutch Brain Research Registry for online study participant recruitment: Design and first results. *Alzheimer's and Dementia*, **2020**, 16, e044738	1.2
211	What patients want to know, and what we actually tell them: The ABIDE project. *Alzheimer's and Dementia*, **2020**, 16, e044754	1.2
210	An RCT to identify best practices for disclosure of amyloid imaging results in mild cognitive impairment: The ABIDE simulation study. *Alzheimer's and Dementia*, **2020**, 16, e044761	1.2
209	Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: The SCIENCe project. *Alzheimer's and Dementia*, **2020**, 16, e044783	1.2
208	Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. *Alzheimer's and Dementia*, **2020**, 16, e044787	1.2
207	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in non-demented memory clinic participants. *Alzheimer's and Dementia*, **2020**, 16, e045196	1.2
206	Grey zone amyloid burden heralds future memory decline: The SCIENCe Project. *Alzheimer's and Dementia*, **2020**, 16, e045210	1.2
205	Educational video increases patients' knowledge regarding the lumbar puncture procedure: Results of a randomized controlled trial in clinical practice. *Alzheimer's and Dementia*, **2020**, 16, e045719	1.2
204	Plasma amyloid-β oligomerization assay as a screening test for abnormal amyloid status. *Alzheimer's and Dementia*, **2020**, 16, e045754	1.2
203	CSF biomarkers for frontotemporal dementia and its pathological subtypes. *Alzheimer's and Dementia*, **2020**, 16, e045851	1.2
202	Associations of brain connectivity with disease progression and cognitive dysfunction in autosomal-dominant Alzheimer disease depend on imaging modality. *Alzheimer's and Dementia*, **2020**, 16, e045942	1.2
201	Study partner- and self-reported difficulties in cognitively complex everyday activities in participants without objective cognitive impairment. *Alzheimer's and Dementia*, **2020**, 16, e046015	1.2
200	Attitudes towards genetic susceptibility testing for Alzheimer's disease dementia in cognitively normal adults: A survey study. *Alzheimer's and Dementia*, **2020**, 16, e047393	1.2

199 IC-P-011: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients **2016**, 12, P19-P20

198 P1-418: Clinicians' Views and Attitudes on Shared Decision Making in Diagnostic Testing for Alzheimer's Disease **2016**, 12, P595-P595

197 P2-335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples **2016**, 12, P770-P771

196 P2-342: Thinner Cortical Thickness in Patients with Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function **2016**, 12, P774-P774

195 Interaction between cerebral small vessel disease and neurodegenerative changes298-310

194 O2-13-05: APOLIPOPROTEIN A-1 IS ASSOCIATED WITH DECLINE IN PRECLINICAL AD **2014**, 10, P195-P196

193 O5-02-02: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY **2014**, 10, P291-P292

192 O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA **2014**, 10, P194-P195

191 P1-223: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE **2014**, 10, P385-P386

190 IC-P-009: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN **2014**, 10, P11-P12

189 IC-P-085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE **2014**, 10, P48-P49

188 P1-015: PROTEIN KINASE ACTIVITY DECREASES WITH BRAAK STAGE IN HIPPOCAMPAL POSTMORTEM BRAIN TISSUE AS REVEALED BY USING A PEPTIDE-BASED MICROARRAY PLATFORM **2014**, 10, P309-P309

187 P1-385: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY, A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF A NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER'S DISEASE **2014**, 10, P455-P456

186 O2-07-04: COGNITIVE SUBTYPES IN DEMENTIA DUE TO ALZHEIMER'S DISEASE IDENTIFIED BY LATENT CLASS ANALYSIS **2014**, 10, P178-P179

185 IC-P-077: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY **2014**, 10, P43-P44

184 O4-01-06: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN **2014**, 10, P250-P251

183 O2-14-03: THE REST-ACTIVITY RHYTHM IS RELATED TO THE LEVEL OF PHYSICAL ACTIVITY IN EARLY-ONSET DEMENTIA **2014**, 10, P197-P198

182 IC-P-056: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE **2014**, 10, P31-P32

181 P1-134: LOSS OF NETWORK INTEGRATION IS RELATED TO COGNITIVE IMPAIRMENT IN DEMENTIA WITH LEWY BODIES **2014**, 10, P349-P349

180 P1-149: CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE **2014**, 10, P355-P355

179 P4-273: CEREBROSPINAL FLUID NEUROGRANIN AS A PROGNOSTIC MARKER IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE **2014**, 10, P884-P884

178 O1-02-04: 7T T2*-WEIGHTED MRI REVEALS CORTICAL PHASE DIFFERENCES BETWEEN EARLY- AND LATE-ONSET AD **2014**, 10, P132-P133

177 P1-174: CEREBROVASCULAR DISEASE IN LATE ONSET FRONTAL LOBE SYNDROME **2014**, 10, P363-P363

176 P1-415: STUDY PROTOCOL: THE EFFECT OF PHYSICAL EXERCISE ON CEREBRAL BLOOD FLOW AND COGNITION IN PATIENTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT **2014**, 10, P465-P466

175 P3-158: Grey matter network disruptions are related to amyloid beta in cognitively healthy elderly **2015**, 11, P689-P689

174 P1-174: Diagnostic impact of [18F]flutemetamol amyloid imaging in young onset dementia **2015**, 11, P411-P412

173 P3-072: Are relations between ApoE genotype and ad-related pathology in nondemented elderly mediated by CSF apolipoproteins? **2015**, 11, P644-P644

172 O4-05-04: A four-center study on the effect of polygenic risk score on cerebrospinal fluid markers and memory decline in mild cognitive impairment patients **2015**, 11, P279-P279

171 IC-P-124: Classification of resting-state cerebral perfusion maps from patients with Alzheimer's disease and patients with frontotemporal dementia **2015**, 11, P85-P85

170 P1-093: Dementia and rapid mortality: Who's at risk? **2015**, 11, P374-P374

169 P2-298: Altered plasma and CSF levels of nutrients that enhance neuronal phospholipid synthesis in Alzheimer's disease: A retrospective cohort study **2015**, 11, P606-P607

168 Frontotemporale dementie en de psychiatrische differentiaaldiagnose: twee gevalsbeschrijvingen en de rationale van de Laat Ontstaan Frontaal syndroom (LOF)-studie *Tijdschrift Voor Neuropsychiatrie En Gedragsneurologie*, **2013**, 1, 72-79

167 S1-02-02: Clinical and neuropsychological features as predictors from MCI to Alzheimer's-type dementia **2013**, 9, P122-P122

166 O3-05-01: Physical activity, independent functioning and emotional well-being in early-onset dementia **2013**, 9, P526-P526

165 O1-09-01: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting **2013**, 9, P144-P145

164 [P1-09]: DETECTING COGNITIVE DISORDERS USING THE MUISTIKKO WEB-BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS **2017**, 13, P234-P235

163 [P2473]: THE EFFECTS OF AMYLOID ON SEMANTIC COMPLEXITY IN SPONTANEOUS SPEECH IN SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P821-P822

162 [P3161]: GRANULOCYTES: KEY PLAYERS IN PERIPHERAL A CLEARANCE? **2017**, 13, P995-P996

161 [P3026]: PROFILING PERIPHERAL METABOLIC DYSREGULATION IN ALZHEIMER's DISEASE: THE ADDED VALUE OF MULTIPLE SIGNATURES **2017**, 13, P1024-P1025

160 [P3375]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT **2017**, 13, P1102-P1103

159 [P3407]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER's DISEASE **2017**, 13, P1120-P1121

158 [P3422]: CLINICAL AND RADIOLOGICAL FINDINGS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CAA **2017**, 13, P1127-P1128

157 [P3566]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P1195-P1196

156 [P4219]: [18F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P1352-P1353

155 [P4235]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER's PATIENTS AND CONTROLS USING FLORTAUCIPIR **2017**, 13, P1364-P1364

154 [IC-P-037]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER's DISEASE **2017**, 13, P33-P34

153 [IC-P-055]: EFFECT OF APOE-2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER's DISEASE **2017**, 13, P45-P46

152 [IC-P-085]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT **2017**, 13, P69-P69

151 [IC-P-095]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER's DISEASE **2017**, 13, P74-P75

150 [IC-P-106]: PREDICTING PROGRESSION IN PRE-DEMENTIA STAGES OF ALZHEIMER's DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE **2017**, 13, P81-P82

149 [IC-P-110]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P87-P87

148 [IC-P-203]: [18F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P148-P149

147 [IC-P-206]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER's PATIENTS AND CONTROLS USING FLORTAUCIPIR **2017**, 13, P150

146 [TD-P-020]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P166-P167

145 [P1□50]: DECISION TREE ANALYSIS REVEALS TWO CUT-OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS **2017**, 13, P342-P343

144 [P1□26]: DETECTING COGNITIVE DISORDERS USING MUISTIKKO WEB-BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS **2017**, 13, P380-P380

143 [P1□40]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P451-P451

142 [P1□86]: OCCURRENCE AND PROFILE OF COGNITIVE IMPAIRMENT IN PATIENTS WITH HEART FAILURE, CAROTID OCCLUSIVE DISEASE AND VASCULAR COGNITIVE IMPAIRMENT: THE HEART-BRAIN CONNECTION STUDY **2017**, 13, P475-P476

141 [P2□07]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID-□AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS **2017**, 13, P688-P688

140 [P2□42]: PROTEOMICS IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES OF DEMENTIA WITH LEWY BODIES **2017**, 13, P704-P704

139 [P2□49]: CONTACTIN-1 IN CSF DISCRIMINATES DEMENTIA WITH LEWY BODIES (DLB) FROM AD AND NON-DEMENTED CONTROLS **2017**, 13, P708-P708

138 [P2□35]: EFFECT OF APOE □ ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER's DISEASE **2017**, 13, P748-P750

137 [F1□03□04]: BIOMARKER-BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P177

136 [O1□01□02]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER's DISEASE **2017**, 13, P182

135 [O1□05□03]: CSF AMYLOID BETA 1□42 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSIS-DEPENDENT UPWARD DRIFT **2017**, 13, P198-P199

134 [O1□05□04]: CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER's DISEASE: AN ASSAY COMPARISON STUDY **2017**, 13, P199

133 [O2□01□01]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE) **2017**, 13, P547-P548

132 [O2□10□06]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM **2017**, 13, P579

131 [O2□11□03]: PREDICTING PROGRESSION IN PRE-DEMENTIA STAGES OF ALZHEIMER's DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE **2017**, 13, P581-P582

130 [O3□06□04]: PROMINENT NON-MEMORY DEFICITS IN AD ARE ASSOCIATED WITH A FASTER DISEASE PROGRESSION **2017**, 13, P912

129 [DT-01□02]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT **2017**, 13, P1474-P1475

128 [P3□75]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS **2017**, 13, P960-P961

127 P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease **2015**, 11, P414-P414

126 IC-P-079: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease **2015**, 11, P57-P57

125 IC-04-03: Grey matter network disruptions are related to amyloid-beta in cognitively healthy elderly **2015**, 11, P11-P11

124 IC-P-062: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease **2015**, 11, P46-P47

123 O3-09-02: An eeg study into functional connectivity and hubs in Alzheimer's disease: What's going on in the posterior regions? **2015**, 11, P237-P238

122 P1-166: A prospective validation study of the predictnd tool: A diagnostic decision support toolRationale and design of the study **2015**, 11, P408-P408

121 O2-02-06: Slow gait speed and low grip strength are related to worse attention and mental speed in patients with subjective cognitive decline and mild cognitive impairment **2015**, 11, P177-P177

120 F2-03-03: Characterization of the behavioral and dysexecutive variants of Alzheimer's disease **2015**, 11, P168-P168

119 P3-142: Alzheimer's biomarkers in daily practice (ABIDE): Study design **2015**, 11, P679-P680

118 IC-P-089: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent? **2015**, 11, P62-P62

117 P4-100: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent? **2015**, 11, P814-P814

116 O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset **2015**, 11, P140-P142

115 O3-14-02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool **2015**, 11, P254-P255

114 F4-02-02: The influence of severity of total comorbidity on cognitive decline and conversion to dementia in memory clinic visitors **2015**, 11, P260-P261

113 O5-02-03: Reduced cortical thickness in patients with subjective cognitive decline is related to clinical progression **2015**, 11, P317-P317

112 O5-05-03: Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease **2015**, 11, P326-P326

111 PL-02-02: PREDICTING CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE **2014**, 10, P162-P163

110 O3-06-02: A RE-EVALUATION OF EARLY ALZHEIMER'S DISEASE BIOMARKERS ACCOUNTING FOR INACCURACY OF THE CLINICAL DIAGNOSIS **2014**, 10, P219-P219

109	S2-02-01: Understanding (endo)phenotypical heterogeneity: The role of age and APOE **2012**, 8, P228-P228	
108	O4-03-01: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease **2012**, 8, P618-P618	
107	F1-01-01: Early-onset versus late-onset Alzheimer's disease: A role for APOE e4? **2011**, 7, S89-S89	
106	Cerebral microbleeds and Alzheimer's disease117-124	
105	Reply: Cerebral microbleeds in familial Alzheimer's disease. *Brain*, **2012**, 135, e202-e202	11.2
104	De diagnostische waarde van de Visuele Associatie Test (vat) in een geheugenpoliklinieksetting. *Neuropraxis*, **2008**, 12, 3-8	0
103	A 24-year follow-up of body mass index and cerebral atrophy. *Neurology*, **2005**, 64, 1990-1; author reply 1990-1	6.5
102	NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia. *Neurology*, **2005**, 65, 1341	6.5
101	Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping.. *Alzheimer's Research and Therapy*, **2022**, 14, 22	9
100	Clinical Evaluation and Treatment of Cognitive Dysfunction and Dementia **2009**, 103-127	
99	P1-297: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients **2016**, 12, P534-P535	
98	IC-03-02: Grey Matter Connectivity is Associated with Clinical Progression in Non-Demented, Amyloid Positive Patients **2016**, 12, P9-P10	
97	P2-221: Cerebral Blood Flow Measured with Phase-Contrast MRI in AD, MCI and Controls **2016**, 12, P706-P706	
96	IC-P-196: Quantification of TAU Load Using [18F]AV-1451 and PET **2016**, 12, P141-P142	
95	O3-08-01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status **2016**, 12, P303-P303	
94	P1-178: Impact of Co-Morbid Amyloid Pathology on Clinical Phenotype of Patients with Vascular Cognitive Disorders **2016**, 12, P472-P472	
93	IC-03-05: EEG Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimer's Disease And Controls **2016**, 12, P12-P12	
92	P1-284: Grey Matter Connectivity is Associated With Clinical Progression in Non-Demented, Amyloid Positive Patients **2016**, 12, P528-P529	

91 P1-327: Cross-Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease **2016**, 12, P552-P553

90 IC-P-097: A Novel Neuroimaging Approach to Capture Cognitive Reserve **2016**, 12, P74-P75

89 IC-P-103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer Disease **2016**, 12, P78-P79

88 IC-P-106: Cross-Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease **2016**, 12, P80-P81

87 IC-P-108: Cerebral Blood Flow Measured With Phase-Contrast MRI in AD, MCI and Controls **2016**, 12, P82-P82

86 P2-348: Impact of Non-Pharmacologic Interventions on Cognitive, Behavioral, and Emotional Functioning in Older Adults with Subjective Cognitive Decline: A Systematic Review of Controlled Trials **2016**, 12, P777-P777

85 P2-282: EEG-Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimer's Disease and Controls **2016**, 12, P738-P738

84 IC-P-147: Atrophy Patterns Predicting Cognitive Decline in Non-Demented Subjects are Independent of Amyloid Pathology **2016**, 12, P109-P110

83 P3-144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts **2016**, 12, P873-P874

82 P4-112: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Non-Demented Elderly **2016**, 12, P1055-P1056

81 P4-191: A Novel Neuroimaging Approach to Capture Cognitive Reserve **2016**, 12, P1095-P1096

80 P4-215: Quantification of Tau Load Using [18F]AV-1451 and Pet **2016**, 12, P1109-P1110

79 P4-240: Deciding About Diagnostic Testing for Alzheimer Disease: Patients Views and Experiences **2016**, 12, P1122-P1122

78 O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer Disease **2016**, 12, P169-P170

77 O1-05-02: Effects of Up to 14 Years of Biobank Storage of CSF Biomarkers AB42, TTAU, and PTAU **2016**, 12, P183-P183

76 O4-02-04: Atrophy Patterns Predicting Cognitive Decline in Non-Demented Subjects are Independent of Amyloid Pathology **2016**, 12, P335-P336

75 O4-09-04: Towards Data-Driven Medicine in Differential Diagnostics of Neurodegenerative Diseases **2016**, 12, P355-P355

74 P1-174: Cost-Efficient Differential Diagnostics of Neurodegenerative Diseases Using A Stratified Approach **2016**, 12, P469-P470

73	IC-P-100: A LONGITUDINAL STUDY OF THE EFFECTS OF EDUCATION AND INTRACRANIAL VOLUME ON COGNITIVE CHANGES AND MORTALITY RATES IN ALZHEIMER'S DISEASE **2019**, 15, P87-P87	
72	F2-01-01: NEURODEVELOPMENTAL DIFFERENCES AND ENVIRONMENTAL INSULTS INVERSELY CORRELATE WITH AGE OF ONSET IN ALZHEIMER'S DISEASE **2019**, 15, P515-P516	
71	IC-P-025: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE **2019**, 15, P32-P33	
70	IC-02-01: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE **2019**, 15, P1-P1	
69	IC-P-076: FDG-PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELY-DEFINED SUBGROUPS OF ALZHEIMER'S DISEASE **2019**, 15, P68-P70	
68	IC-P-015: VOXEL-BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE CONTINUUM **2019**, 15, P24-P25	
67	P1-291: THE ASSOCIATION BETWEEN AFFECTIVE SYMPTOMS AND ALZHEIMER'S DISEASE BIOMARKERS ACROSS THE DISEASE SPECTRUM **2019**, 15, P355-P355	
66	Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [F]Flortaucipir and [F]Florbetapir Brain PET Studies. *Molecular Imaging and Biology*, **2021**, 23, 550-559	3.8
65	P1-256: COMMUNICATION ON DIAGNOSTIC TESTING FOR (ALZHEIMER'S) DEMENTIA: THE ABIDE-CLINICAL ENCOUNTER STUDY **2018**, 14, P378-P379	
64	P3-403: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE **2018**, 14, P1257-P1257	
63	O1-10-06: CONTACTIN-1 HAS ADDED VALUE FOR DISCRIMINATION OF DEMENTIA WITH LEWY BODIES FROM ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE **2018**, 14, P245-P246	
62	P1-476: CORTICAL T1-W/T2-W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS **2018**, 14, P506-P507	
61	O1-14-04: IMPACT OF WHITE MATTER HYPERINTENSITY LOCATION ON DEPRESSIVE SYMPTOMS IN MEMORY CLINIC PATIENTS: A LESION-SYMPTOM MAPPING STUDY **2018**, 14, P259-P259	
60	IC-P-111: [18F]FLORBETAPIR-SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE **2018**, 14, P95-P96	
59	IC-P-222: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM **2018**, 14, P180-P181	
58	P1-328: CONSISTENCY OF MUISTIKKO WEB-BASED COGNITIVE TEST WHILE PERFORMED AT CLINIC AND AT HOME **2018**, 14, P418-P418	
57	P2-645: IMPAIRED OLFACTORY AND GUSTATORY FUNCTIONING IN PATIENTS WITH ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT: THE NUDAD PROJECT **2018**, 14, P990-P990	
56	P2-350: DETECTING FRONTOTEMPORAL DEMENTIA USING A NOVEL MRI IMAGING BIOMARKER: THE ANTERIOR VERSUS POSTERIOR INDEX **2018**, 14, P821-P822	

55 P1-357: MEDIAN SURVIVAL IN MEMORY CLINIC COHORT IS SHORT, EVEN IN YOUNG-ONSET DEMENTIA **2018**, 14, P431-P431

54 P1-016: METHYLPHENIDATE IMPROVES EXECUTIVE FUNCTIONING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT: FIRST RESULTS OF THE STREAM-VCI STUDY **2018**, 14, P270-P271

53 P1-259: SEX DIFFERENCES IN CEREBROSPINAL FLUID BIOMARKER CONCENTRATIONS ACROSS CLINICAL STAGES OF ALZHEIMER'S DISEASE **2018**, 14, P380-P380

52 O2-06-03: AMYLOID-□LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE **2018**, 14, P632-P632

51 P2-248: CONTACTIN-2 AS A POTENTIAL BIOMARKER FOR MILD COGNITIVE IMPAIRMENT **2018**, 14, P768-P768

50 IC-06-05: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE **2018**, 14, P13-P13

49 P2-228: PRE-ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA **2018**, 14, P755-P756

48 P3-134: CIRCULATING METABOLITES ARE ASSOCIATED WITH WHITE MATTER HYPERINTENSITIES **2018**, 14, P1119-P1119

47 P1-297: METABOLIC BLOOD-BASED BIOMARKERS RELATE TO BRAIN ATROPHY AND WHITE MATTER HYPERINTENSITIES IN ALZHEIMER'S DISEASE **2018**, 14, P401-P403

46 P3-438: PARAMETRIC IMAGING OF [18F]FLORBETAPIR: A TEST-RETEST STUDY IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER'S DISEASE **2018**, 14, P1281-P1282

45 P3-289: HARMONIZATION OF SCD OPERATIONALIZATION ACROSS DIFFERENT MEMORY CLINIC SETTINGS: THE EURO-SCD STUDY **2018**, 14, P1191-P1191

44 O2-09-03: DIAGNOSTIC PERFORMANCE OF ELECSYS IMMUNOASSAYS FOR CEREBROSPINAL FLUID ALZHEIMER'S DISEASE BIOMARKERS IN A NON-ACADEMIC MULTICENTER MEMORY CLINIC COHORT: THE ABIDE PROJECT **2018**, 14, P641-P642

43 P2-349: DIFFERENT COMBINATIONS OF DIAGNOSTIC TESTS DISCRIMINATE SPECIFIC SUBTYPES OF DEMENTIA **2018**, 14, P820-P821

42 P2-352: COMMUNICATING UNCERTAINTY WHEN DISCLOSING DIAGNOSTIC TEST RESULT: THE ABIDE-CLINICAL ENCOUNTER STUDY **2018**, 14, P823-P823

41 P1-656: NUTRITIONAL STATUS AND BODY COMPOSITION OF PATIENTS WITH AD, MCI AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD PROJECT **2018**, 14, P593-P594

40 P2-363: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS **2018**, 14, P830-P831

39 P2-134: THE ADDED VALUE OF EXTREME PHENOTYPES IN ALZHEIMER'S DISEASE CASE-CONTROL STUDIES **2018**, 14, P719-P719

38 P2-360: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM **2018**, 14, P827-P829

37 P3-264: UNBIASED METHOD TO DETERMINE CUT-POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION **2018**, 14, P1176-P1177

36 O2-03-03: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY **2018**, 14, P615-P617

35 P4-038: IS SORL1 AN AUTOSOMAL DOMINANT ALZHEIMER GENE? **2018**, 14, P1447-P1447

34 P2-500: PHYSICAL PERFORMANCE IN RELATION TO COGNITIVE FUNCTIONING IN PATIENTS WITH DISORDERS ALONG THE HEART-BRAIN AXIS **2018**, 14, P921-P921

33 O2-06-01: [18F]FLORBETAPIR SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE **2018**, 14, P630-P631

32 O5-04-01: A RARE GENETIC VARIANT IN THE PLCG2 GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE **2018**, 14, P1648-P1649

31 IC-P-093: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS **2018**, 14, P79-P80

30 IC-P-033: LONGITUDINAL CHANGES IN GREY MATTER CONNECTIVITY ARE RELATED TO COGNITIVE DECLINE IN PRODROMAL ALZHEIMER'S DISEASE **2018**, 14, P37-P38

29 P3-342: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTI-STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES **2018**, 14, P1214-P1215

28 IC-P-032: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTI-STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES **2018**, 14, P36-P37

27 F5-05-04: THE USE OF RESIDUAL METHODS TO CAPTURE COGNITIVE RESERVE AND STUDY CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE **2018**, 14, P1633-P1633

26 P1-467: DISEASE-STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE **2018**, 14, P500-P501

25 O3-13-06: TAKING AMYLOID PET INTO THE CLINIC: INDIVIDUALIZED RISK PREDICTION IN MCI PATIENTS THE ABIDE PROJECT **2018**, 14, P1058-P1058

24 O2-15-06: CSF AMYLOID- PEPTIDES IN DEMENTIA WITH LEWY BODIES AND ALZHEIMER'S DISEASE **2018**, 14, P663-P664

23 O3-14-03: IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES FOR DEMENTIA WITH LEWY BODIES: A PROTEOMIC APPROACH **2018**, 14, P1060-P1060

22 O2-15-04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS **2018**, 14, P661-P662

21 O5-01-03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NON-NEGATIVE MATRIX FACTORIZATION **2018**, 14, P1638-P1639

20 P2-284: NUTRITIONAL MARKERS ASSOCIATED WITH CLINICAL PROGRESSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD STUDY **2018**, 14, P789-P790

19	P3-617: NUTRITIONAL INTAKE IN SUBJECTIVE COGNITIVE DECLINE: ROOM FOR IMPROVEMENT? **2018**, 14, P1366-P1367	
18	Diagnostiek van de ziekte van Alzheimer. *Neuropraxis*, **2018**, 22, 172-179	0
17	F4-08-01: PLASMA AMYLOID AS A PRE-SCREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITIVE DECLINE **2018**, 14, P1394-P1394	
16	IC-P-187: CORTICAL T1-W/T2-W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS **2018**, 14, P156-P156	
15	Sex and Cardiovascular Function in Relation to Vascular Brain Injury in Patients with Cognitive Complaints. *Journal of Alzheimer's Disease*, **2021**, 84, 261-271	4.3
14	Comparing a Single Clinician Versus a Multidisciplinary Consensus Conference Approach for Dementia Diagnostics. *Journal of Alzheimer's Disease*, **2021**, 83, 741-751	4.3
13	A Cystatin C Cleavage ELISA Assay as a Quality Control Tool for Determining Sub-Optimal Storage Conditions of Cerebrospinal Fluid Samples in Alzheimer's Disease Research. *Journal of Alzheimer's Disease*, **2021**, 83, 1367-1377	4.3
12	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. *Cerebral Circulation - Cognition and Behavior*, **2022**, 3, 100128	0
11	Psychosocial effects of Corona virus measures on (pre-)dementia patients during 2 lockdown.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 7, e053995	1.2
10	Young-onset dementia in memory clinics in the Netherlands: PRECODE-GP.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 8, e053524	1.2
9	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy **2020**, 15, e0226784	
8	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy **2020**, 15, e0226784	
7	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy **2020**, 15, e0226784	
6	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy **2020**, 15, e0226784	
5	Clinicians□ communication with patients receiving a MCI diagnosis: The ABIDE project **2020**, 15, e0227282	
4	Clinicians□ communication with patients receiving a MCI diagnosis: The ABIDE project **2020**, 15, e0227282	
3	Clinicians□ communication with patients receiving a MCI diagnosis: The ABIDE project **2020**, 15, e0227282	
2	Clinicians□ communication with patients receiving a MCI diagnosis: The ABIDE project **2020**, 15, e0227282	

1 The majority of the patients with a monogenic predisposition for dementia did not fulfill current criteria for genetic testing.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 3, e052075 1.2